RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma

Table 1 Association between RRM2 expression and clinicopathologic characteristics (logistic regression)

Clinical characteristics	Total (N)	Odds ratio (OR) in RRM2 expression	p-value
Age	494
≤ 65 vs. > 65		0.7464644 (0.5234463–1.06287)	0.1053727
Gender	513
Male vs. Female		1.357798 (0.9591132–1.925223)	0.08510176
Stage	505
II vs. I		1.55754 (1.014021–2.399717)	0.04346904*
III vs. I		2.180556 (1.327597–3.627003)	0.002300152**
IV vs. I		3.019231 (1.30853–7.578007)	0.01244337*
T	510
T2 vs. T1		1.959701 (1.329787–2.902402)	0.0007191007***
T3 vs. T1		1.326567 (0.6885868–2.545255)	0.3947867
T4 vs. T1		1.674959 (0.6424348–4.427256)	0.2882927
N	501
N2 vs. N1		1.75431 (1.108522–2.796568)	0.0170222*
N3 vs. N1		2.50069 (1.487095–4.295968)	0.0006760279***
N4 vs. N1		1.275862 (0.05016816–32.44753)	0.8636424
M	369
M1 vs. M0		2.252246 (0.9743585–5.647803)	0.06628612

ISSN: 2045-3701